依登载时间排序 Chronological

12/26/2021: 最近进展Recent Progress–>NanoTherm 治疗中危前列腺癌 NanoTherm therapy for intermediate-risk prostate cancer

12/25/2021: 最近进展Recent Progress–>Elacestrant 改善了转移性乳腺癌的无进展生存期 Elacestrant improved progression-free survival in metastatic breast cancer

12/19/2021: 最近进展Recent Progress–>派姆单抗加化疗对持续性、复发性或转移性宫颈癌的疗效 Pembrolizumab plus chemotherapy in persistent, recurrent or metastatic cervical cancer

12/18/2021: 最近进展Recent Progress–>抗组胺药增加免疫疗法对癌症的效果 Antihistamines drugs may influence efficacy of checkpoint inhibitor in cancer therapy

12/12/2021: 最近进展Recent Progress–>Mirvetuximab soravtansine对耐铂类药卵巢癌的治疗 Mirvetuximab soravtansine in platinum-refractory ovarian cancer

12/11/2021: 最近进展Recent Progress–>个性化癌症疫苗用于胶质母细胞瘤 A personalized cancer vaccine used in glioblastoma

12/5/2021: 最近进展Recent Progress–>NC201 对复发性具有 H3 K27M 突变的弥漫性中线胶质瘤的疗效 NC201 in treating relapsed diffuse midline glioma with H3 K27M mutation

12/4/2021: 最近进展Recent Progress–>Ibrutinib与利妥昔单抗联合作为第一线治疗老年套细胞淋巴瘤 Ibrutinib and rituximab combination as first-line chemotherapy-free regime for elderly mantel cell lymphoma

11/28/2021: 最近进展Recent Progress–>Durvalumab联合化疗与单独化疗相比改善了晚期胆道癌生存率 Durvalumab and chemotherapy combination showed better overall survival in advanced biliary tract cancer than chemotherapy alone

11/27/2021: 最近进展Recent Progress–>DNX-2401 治疗弥漫性内在性脑桥胶质瘤 DNX-2401 treating diffuse intrinsic pontine glioma （DIPG）

11/21/2021: 最近进展Recent Progress–>Tisotumab vedotin 对先前治疗过的复发性或转移性宫颈癌中的疗效 Efficacy of Tisotumab vedotin in previously treated recurrent of metastatic cervical cancer

11/20/2021: 最近进展Recent Progress–>携带CDH1变异的遗传性小叶乳腺癌和隐匿性胃癌 CDH1 variant-associated hereditary lobular breast cancer and occult gastric cancer

11/14/2021: 最近进展Recent Progress–>III 期临床试验测试Nemvaleukin α用于铂类耐药卵巢癌 Nemvaleukin alfa for platinum-resistant ovarian cancer in phase III clinical trial

11/13/2021: 最近进展Recent Progress–>FDA 批准asciminib用于治疗费城染色体阳性慢性粒细胞白血病 FDA granted approval to asciminib for patients with Ph+ CML in chronic phase

11/7/2021: 最近进展Recent Progress–>派姆单抗用于高风险II期黑色素瘤切除后的疗效 Pembrolizumab in high-risk stage II melanoma following resection

11/6/2021: 最近进展Recent Progress–>抗体-药物偶联物 trastuzumab deruxtecan (T-DXd) 作为二线药物用于晚期HER2 阳性乳腺癌 Trastuzumab deruxtecan as second line therapy for advanced stage HER-2-positive breast cancer

10/31/2021: 最近进展Recent Progress–>联合伊匹单抗和纳武单抗治疗软脑膜癌病 Treating leptomeningeal carcinomatosis with combination of ipilimumab and nivolumab

10/30/2021: 最近进展Recent Progress–>卡博替尼显示对肾癌脑转移的活性 Activity of cabozantinib in renal cell carcinoma with brain metastases

10/24/2021: 最近进展Recent Progress–>Mosunetuzumab 治疗多次复发滤泡性淋巴瘤 Mosunetuzumab treating recurrent/refractory follicular lymphoma

10/23/2021: 最近进展Recent Progress–>Adavosertib用于对 PARP 抑制剂耐药的卵巢癌 Adavosertib for ovarian cancer refractory to PARP inhibitor

10/17/2021: 最近进展Recent Progress–>阿比特龙在雄激素受体阳性唾液腺肿瘤中具有活性 Abiraterone showed activity in andorgn-receptor positive salivary gland cancer

10/16/2021: 最近进展Recent Progress–>Durvalumab与化疗联用提高广泛期小细胞肺癌的生存率 Durvalumab and chemotherapy combination prolonged overall survival in extensive-stage small cell lung cancer

10/10/2021: 最近进展Recent Progress–>早期乳腺癌腋窝淋巴结的处理（II, 接受术前化疗患者) Management of the axilla in early-stage breast cancer (II, following neoadjuvant chemotherapy)

10/9/2021: 最近进展Recent Progress–>早期乳腺癌腋窝淋巴结的处理: 安大略健康和ASCO指南部分摘要 (10/9/2021) (I, 未接受术前化疗患者) Management of the axilla in early-stage breast cancer: Ontario health and ASCO guideline (I, without neoadjuvant chemotherapy)

10/3/2021: 最近进展Recent Progress–>Adavosertib 用于 TP53 和 RAS 突变的转移性结直肠癌 Adavosertib for metastatic colorectal cancer with TP53 and RAS muutatons

10/2/2021: 最近进展Recent Progress–>在雄激素剥夺疗法中加入阿比特龙可改善高危前列腺癌的生存率 Abiraterone added to ADT improved survival among high-risk prostate patients

9/26/2021: 最近进展Recent Progress–>口服地西他滨（decitabine）和 cedazuridine治疗骨髓增生异常综合征和慢性粒单核细胞白血病 Oral decitabine and cedazuridine in treating MDS and CMML

9/25/2021: 最近进展Recent Progress–>转移性膀胱尿路上皮癌的第一线免疫疗法相比于化疗 First line immunotherapy versus chemotherapy in metastatic urothelial cancer of the bladder

9/19/2021: 最近进展Recent Progress–>比较两种手术前后化疗方案在肌肉浸润性膀胱癌患中的疗效 Comparison of two neoadjuvant and adjuvant chemotherapy regimes in muscle-invasive bladder cancer

9/18/2021: 最近进展Recent Progress–>Oleclumab 或 monalizumab 与度伐单抗联用有益于不可切除的非小细胞肺癌 Oleclumab or monalizumab in combination with Durvalumab showed clinical benefit in unresectable NSCLC

9/12/2021: 最近进展Recent Progress–>PARP 抑制剂治疗与继发性恶性肿瘤风险 PARP inhibitor use and risk of secondary malignancy

9/11/2021: 最近进展Recent Progress–>TROP2 抗体-药物偶联物治疗非小细胞肺癌 TROP2 antibody-drug conjugate in treating non-small cell lung cancer

9/5/2021: 最近进展Recent Progress–>Alrizomadlin 用于对PD-1 阻断剂耐药的肿瘤 Alrizomadlin used in tumors that were resistant to PD-1 inhibitor

9/4/2021: 最近进展Recent Progress–>前列腺癌根治术后辅助放疗与早期挽救性放疗对高危复发性患者死亡风险的影响 Impact of adjuvant versus early salvage radiation following radical prostatectomy on risk of death among patients with high risk of recurrence

8/29/2021: 最近进展Recent Progress–>比较Cabaztaxel与紫杉醇化疗作为 HER2 阴性转移性乳腺癌的 一线治疗 Comparison of cabazitaxel and paclitaxel as first line therapy for HER-2-negative metastatic breast cancer

8/28/2021: 最近进展Recent Progress–>Leronlimab 治疗转移性三阴性乳腺癌 Leronlimab for triple-negative beast cancer

8/22/2021: 最近进展Recent Progress–>在吉西他滨（gemcitabine）中加入 Adavosertib 治疗耐铂的浆液性卵巢癌 Adavosertib plus gemcitabine for platinum-refractory high-grade serous ovarian cancer

8/21/2021: 最近进展Recent Progress–>Tivozanib用于复发或难治性晚期肾细胞癌 Tivozanib for refractory or relapsed renal cell cancer

8/15/2021: 最近进展Recent Progress–>免疫抑制剂派姆单抗（pembrolizumab）联合化疗作为新辅助治疗高危早期三阴性乳腺癌 Pembrolizumab in combination with chemotherapy for high-risk early-stage triple-negative breast cancer （也刊于实体瘤->乳腺->三阴性乳腺癌; Please also see Solid Tumor–>Breast–>Triplr-negative）

8/14/2021: 最近进展Recent Progress–>Amivantamab 与 lazertinib 联用可能治疗奥希替尼（Osimertinib）而复发的非小细胞肺癌 Combination of Amivantamab and lazertinib may overcome osimertinib-resistance in non-small cell lung cancer patients

8/8/2021: 最近进展Recent Progress–>数据库研究显示他汀类药物可能有利于三阴性乳腺癌患者 Retrospective data analyses suggested possible benefit of Statin in triple-negative breast cancer

8/7/2021: 最近进展Recent Progress–>双特异性抗体Amivantamab治疗非小细胞肺癌 Bispecific antibody Amivantamab in treating non-small cell lung cancer

8/1/2021: 最近进展Recent Progress–>临床试验BBP-398与nivolumab联合治疗具有 KRAS 突变的晚期实体瘤 Clinical trial to study the combination of BBP-398 with nivolumab in advanced solid tumors with KRAS mutation

7/31/2021: 最近进展Recent Progress–>Eganelisib 联合纳武单抗 (Nivolumab) 治疗铂类难治性尿路上皮癌 Eganelisib in combination with Nivolumab in treating cisplatin-refractory urothelial cancer

7/25/2021: 最近进展Recent Progress–>首例研究性磁性装置在人体试验中缩小胶质母细胞瘤 Oncomagnetic device treatment in a first case of recurrent glioblastoma

7/24/2021: 最近进展Recent Progress–>术后pembrolizumab延长高危肾细胞癌的无病生存期 Adjuvant pembrolizumab extends disease-free survival in high-risk renal cell carcinoma

7/18/2021: 最近进展Recent Progress–>Olaparib 用于 BRCA1 或 BRCA2 突变的乳腺癌患者的辅助治疗 Olaparib for adjuvant use in BRCA1/2-mutated breast cancer

7/17/2021: 最近进展Recent Progress–>Lifileucel用于疾病进展后的转移性黑色素瘤 Lifileucel used in metastatic melanoma after disease progression

7/11/2021: 最近进展Recent Progress–>使用抗生素与早发性结直肠癌之间是否存在联系？Is there a link between antibiotics use and early-onset of colorectal cancer?

7/10/2021: 最近进展Recent Progress–>分子成像可改善胰腺导管腺癌的分期和治疗 Molecular imaging may improve staging and treatment of pancreatic ductal cancer

7/4/2021: 最近进展Recent Progress–>抗寄生虫药ivermectin在治疗乳腺癌中的应用 Anti-parasitic drug Ivermectin in treating breast cancer

7/3/2021: 最近进展Recent Progress–>FDA 批准piflufolastat F 18用于前列腺特异性膜抗原（PSMA）PET成像的药物 Piflufolastat F 18 was approved by FDA as a PSMA targeted PET imaging agent in prostate cancer

6/27/2021: 最近进展Recent Progress–>恩杂鲁胺（Enzalutamide）联合化疗治疗晚期或复发性子宫内膜癌 Enzalutamide in combination with Paclitaxel and carboplatin in advanced or recurrent endometrioid endometrial cancer

6/26/2021: 最近进展Recent Progress–>一种新型选择性雌激素受体降解剂Elacestrant对雌激素受体阳性转移性乳腺癌的 I期研究 Phase I study of a novel selective ER degrader in ER-positive advanced breast cancer

6/20/2021: 最近进展Recent Progress–>纳武单抗作为肌肉浸润性尿路上皮癌的辅助治疗改善生存 Adjuvant Nivolumab improved survival in muscle-invasive urothelial cancer

6/19/2021: 最近进展Recent Progress–>FDA 加速批准 dostarlimab-gxly 用于错配修复缺陷( dMMR) 子宫内膜癌  Dostarlimab was granted accelerated approval for dMMR endometrial cancer

6/13/2021: 最近进展Recent Progress–>针对RET 融合性实体瘤的Selpercatinib 的益处扩展到肺癌和甲状腺癌之外  Clinical benefit of Selpercatinib to RET-fusion-positive tumor beyond lung and thyroid cancer

6/12/2021: 最近进展Recent Progress–>Ixabepilone加贝伐单抗对铂类耐药或复发性卵巢癌有效 Ixabepilone plus bevacizumab active for platinum-refractory or recurrent ovarian cancer

6/6/2021: 最近进展Recent Progress–>伊匹单抗/纳武单抗/帕尼单抗联用在 RAS/BRAF 野生型/微卫星稳定的转移性结直肠癌 Combination of ipilimumab/nivolumab/panitumumab used in RAS/BRAF wild-type/microsatellite stable metastatic colorectal cancer

6/5/2021: 最近进展Recent Progress–>术后Nivolumab（纳武单抗）治疗食管癌或胃食管交界处癌 Adjuvant Nivolumab for Resected Esophageal or Gastroesophageal Junction Cancer

5/30/2021: 最近进展Recent Progress–>单剂量放疗用于乳腺癌治疗 Single dose adjuvant radiation for breast cancer

5/29/2021: 最近进展Recent Progress–>Nivolumab联合化疗可提高术前非小细胞肺癌患者的病理完全响应 Pre-operative Nivolumab in combination with chemotherapy increased pathologic complete response rate among NSCLC patients

5/23/2021: 最近进展Recent Progress–>Tislelizumab联合化疗作为转移性鼻咽癌的一线治疗 Tislelizumab in combination with chemotherapy as first line therapy for metastatic nasopharyngeal cancer

5/22/2021: 最近进展Recent Progress–>一项新的药物敏感测试确定卵巢透明细胞癌的新治疗方法 A new drug sensitivity assay identifies therapeutic options for clear cell carcinoma of the ovary

5/16/2021: 最近进展Recent Progress–>Copanlisib-rituximab组合可降低惰性非霍奇金淋巴瘤的疾病进展或死亡 Combination of copanlisib-rituximab may reduce disease progression and death in indolent NHL

5/15/2021: 最近进展Recent Progress–>对已扩散到大脑的乳腺癌细胞的潜在新治疗策略 Potential new treatment strategy for breast cancer metastatic to the brain

5/9/2021: 最近进展Recent Progress–>新型雄激素受体激动剂Enobosarm治疗乳腺癌的II期临床研究 A phase II trial of a novel androgen receptor agonist, Enobosarm, in breast cancer

5/8/2021: 最近进展Recent Progress–>在术前化疗之前进行完全膀胱尿道切除术和膀胱癌生存率改善有关 Complete transurethral resection of bladder tumor before neoadjuvant chemotherapy was associated with improved survival

5/2/2021: 最近进展Recent Progress–>含有BRAF抑制剂的乳霜可以缓解表皮生长因子受体抑制剂引起的皮丘疹 A novel BRAF-inhibitor containing cream may ameliorate skin rashes caused by EGFR inhibitor

5/1/2021: 最近进展Recent Progress–>Trilaciclib开始在三阴性乳腺癌中进行III期注册临床试验 A phase III clinical trial using Trilaciclib in triple-negative breast cancer is starting

4/25/2021: 最近进展Recent Progress–>放化疗前加上化疗提高局部晚期直肠癌的无病生存率 Neoadjuvant chemotherapy prior to standard chemo-radiation improved DFS in locally advanced rectal cancer

4/24/2021: 最近进展Recent Progress–>包括抗CD38药物daratumumab在内的四药治疗新诊断多发性骨髓瘤方案导致最小残留疾病（MRD） Four drug combination including daratumumab achieved good MRD level in newly diagnosed multiple myeloma patients

4/18/2021: 最近进展Recent Progress–>卡博替尼可能是治疗转移性乳头状肾癌的新标准 Carbozantinib may become the new standard for metastatic papillary kidney cancer

4/17/2021: 最近进展Recent Progress–>对胆管癌持久有效的另一种FGFR抑制剂:Futibatinib Another FGFR inhibitor that generated durable response in cholangial carcinoma

4/11/2021: 最近进展Recent Progress–>LuPSMA优于卡巴他赛用于转移性去势抵抗性前列腺癌 LuPSMA was superior to cabazitaxel in metastatic castration-resistant prostate cancer

4/10/2021: 最近进展Recent Progress–>Tipifarnib用于HRAS突变型晚期头颈癌 Tipifarnib used in advanced HRAS-mutant head and neck cancer

4/4/2021: 最近进展Recent Progress–>Tesetaxel在转移性乳腺癌中实现了主要终点:提高了无进展生存期 Tesetaxel reached primary ob in metastatic breast cancer: improved PFS

4/3/2021: 最近进展Recent Progress–>WEE1抑制剂用于复发性子宫浆液性癌 WEE1 inhibitor in recurrent uterine serous carcinoma

3/28/2021: 最近进展Recent Progress–>FDA加速批准Yescarta用于复发或难治性滤泡性淋巴瘤的三线治疗 FDA has granted accelerated approval to Yescarta as third-line therapy for relapsed or refractory follicular lymphoma

3/27/2021: 最近进展Recent Progress–>III期临床研究显示atezolizumab延长早期非小细胞肺癌患者的寿命 A pivotal phase III study showed atezolizumab prolonged disease-free survival in early-stage non-small cell lung cancer

3/21/2021: 最近进展Recent Progress–>夜班工作会使DNA修复基因的昼夜节律失调: 导致患癌症风险增加的机制? Circadian dysregulation of DNA repair genes among night-shift workers: a mechanism of increase cancer risk?

3/20/2021: 最近进展Recent Progress–>口服紫杉醇/ensequidar组合可提高转移性​​乳腺癌的生存率 Oral paclitaxel/ensequidar improved overall survival in metastatic breast cancer

3/14/2021: 最近进展Recent Progress–>SY-1425加阿扎胞苷将用于RARA-阳性的骨髓增生异常综合征 临床试验 SY-1425 plus Azacitidine will be used in RARA-positive MDS clinical trial

3/13/2021: 最近进展Recent Progress–>卡培他滨和奥沙利铂结合腹膜内紫杉醇有益于腹膜转移的胃癌患者 Systemic oxaliplatin and capecitabine plus intraperitoneal paclitaxel may benefit gastric cancer patients with peritoneal metastases

3/7/2021: 最近进展Recent Progress–>Neratinib对HER2阳性雌激素受体阳性的早期乳腺癌的最终疗效结果 Final results of efficacy results of Neratinib in HER-2/ER-positive early breast cancer

3/6/2021: 最近进展Recent Progress–>PVSRIPO作为孤儿药治疗晚期黑色素瘤 PVSRIPO was granted orphan drug by FDA to treat advanced stage melanoma

2/28/2021: 最近进展Recent Progress–>蓝光膀胱镜检查非肌肉浸润性膀胱癌 Application of blue-light flexible cystoscopy in non-muscle invasive bladder cancer

2/27/2021: 最近进展Recent Progress–>宫颈癌患者术后序贯性放化疗相比于同时放化疗或单独放疗 Sequential chemotherapy/radiation (RT) compared with concurrent chemo/RT or RT alone in cervical cancer following hysterectomy

2/21/2021: 最近进展Recent Progress–>乳腺癌的内部乳腺和内侧锁骨上淋巴结链照射:一项3期临床试验的15年结果 Impact of internal mammary and medial supraclavicular lymph node chain irradiation: 17-year follow-up results

2/20/2021: 最近进展Recent Progress–>开发一种精确的肿瘤活检技术 New technique offers more accurate tumor biopsy

2/14/2021: 最近进展Recent Progress–>Enfortumab Vedotin在耐药性晚期尿路上皮癌中胜过化疗 Enfortumab Vedotin demonstrated benefit in refractory uroepithelial cell carcinoma

2/13/2021: 最近进展Recent Progress–>双重HER2阻断与芳香酶抑制剂联合治疗绝经后激素受体/HER2阳性的转移性乳腺癌 Dual HER-2 blockade plus aromatase inhibitor for postmenopausal women with metastatic ER/HER2-positive breast cancer

2/7/2021: 最近进展Recent Progress–>Margetuximab加上化疗优于曲妥珠单抗加上化疗治疗对HER2阳性晚期乳腺癌 Margetuximab plus chemotherapy more beneficial than trastuzumab/chemo combination in advanced HER-2 positive breast cancer

2/6/2021: 最近进展Recent Progress–>激素受体阳性淋巴结阳性绝经后乳腺癌患者可以避免化疗 Some ER-positive, HER-2-negative and lymph-node-positive postmenopausal breast cancer patients avoid chemotherapy（也刊于实体瘤->乳腺->淋巴结阳性; Please also see Solid Tumor–>Breast–>Lymph Node Positive)）

1/31/2021: 最近进展Recent Progress–>Mobocertinib对EGFR 外显子 20插入突变的IV期非小细胞肺癌有效 Mobocertinib effective to Non-small cell lung cancer harboring EGFR exon 20 insertion mutation

1/30/2021: 最近进展Recent Progress–>血液聚糖检查可识别耐受辅助化疗的胰腺癌 A serum glycan biomarker may detect chemotherapy-resistant pancreatic cancer